Trials / Completed
CompletedNCT01508130
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Non-Interventional, Prospective Cohort Study of the Effectiveness, Safety and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practice in the USA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 672 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1. Patients receiving pegylated interferon (e.g. Pegasys) and ribavirin plus either telaprevir or boceprivir in accordance with local standard of care and US labeling will be followed for the duration of their treatment and for up to 24 weeks post-treatment.
Conditions
Timeline
- Start date
- 2012-01-31
- Primary completion
- 2014-03-31
- Completion
- 2014-03-31
- First posted
- 2012-01-11
- Last updated
- 2017-04-10
- Results posted
- 2016-02-22
Locations
66 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01508130. Inclusion in this directory is not an endorsement.